Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Senseonics Holdings Inc (SENS)

NYSE
Currency in USD
Disclaimer
0.464
-0.018(-3.66%)
Closed
After Hours
0.487+0.023(+4.957%)

SENS Comments

https://www.investing.com/news/assorted/savings-offer-for-the-eversense-e3-cgm-extended-to-cover-unlimited-number-of-systems-93CH-3333900
to the moon 🌙
Literally very bad stock to invest in
Interesting to see in the next 5 years. Reminds me of how Dexcom was when they first started. Patience will pay off.
Will there be a buyer or is it false rumor?
what's up?
is Dexcom looking to buy Sens? Thoughts
There could be something in this rumor. Current market cap would make it plausible too.
What’s wrong with this stock?
It’s about the market i guess
It has likely been selected among several other small companies as a target for predatory naked shorting by MMs.
This is only the beginning! We will be going further than the moon....to the next universe!!!
why?🤦😁😁😁
Do you not agree? Sensonics has many shareholders who are blue chip companies. There are also several big medical insurance companies that are covering their GCMs.
sens to the moon
good news for SENS
Washington Business Journal - By Sara Gilgore Staff Reporter, Washington Business Journal Jun 20, 2022. "Senseonics earns 😊"Green Light" to take longer-lasting diabetes device international" The Germantown med-tech firm makes an implantable continuous glucose monitoring system for diabetes patients. Senseonics earns approval to launch 180-day diabetes device in European Union. Germantown’s Senseonics Holdings Inc. is charging forward with a go-ahead to launch its implantable continuous glucose monitoring (CGM) device for diabetes patients in Europe, about four months after earning U.S. regulatory approval for the product. 👉The company, which said Thursday it scored CE Mark approval for the device, is working with Switzerland’s Ascensia Diabetes Care to commercialize the six-month system, a longer-lasting version of the local company’s 90-day CGM device already on the market. 👉The new product, called Eversense E3, is expected to go live in the third quarter in European Union countries including Germany, Italy, Spain, the Netherlands, Poland, Switzerland, Norway and Sweden, according to Senseonics. 👉The approval strengthens the med-tech firm’s market position and “enables increased operational efficiency as Senseonics will now commercialize the same product iteration globally for the first time,” Senseonics President and 💥CEO Tim Goodnow said in a statement. “We are excited for Ascensia to continue to build on the momentum of the E3 launch in the U.S. as they commercialize the improved system in European markets in the coming months.” 👉It follows the FDA’s February approval of the 180-day Eversense product, which came after more than a year of delays in the agency’s review of the company’s application driven by the Covid-19 pandemic. That news Feb. 11 sent the company’s stock to a high of $3.27 at a trading volume of 106.37 million. Senseonics (NYSE: SENS) saw its stock hit a high of $1 Thursday on the news of the CE approval, before closing up 2.23% at 97 cents. 👉The U.S. approval followed the biotech’s 2020 deal with Ascensia, which helped the business regain its footing. That came during a rocky pandemic period — involving the suspension of U.S. commercial sales and a strategic review of the business. Now, 💥💥the green light in Europe propels Senseonics even farther ahead in the competition to make the longest-lasting CGM system widely available, as competitors including 👉Medtronic, Abbot and Dexcom market devices that last a couple of weeks. The company is separately developing a version of Eversense for patients to wear for up to a year. We have reached out for a status update and other details around what’s next, and will update this post as we hear back
US stockmarket is 99% rigged casino.
It is what it is brother.
https://www.ascensia.com/press/press-releases/press-release/?id=e82a55cd-2a2a-4aa4-9ad9-d1322611958e
Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the Eversense® NOW Remote Monitoring App for the Android Operating System in Europe. With this launch, remote monitoring capabilities are now available for all Eversense® and Eversense® XL Continuous Glucose Monitoring (CGM) users on Android and iOS operating systems in the US and Europe, respectively.Developed by Senseonics and brought to people with diabetes by Ascensia, Eversense is the world’s first and only long-term continuous glucose monitoring system. The Eversense NOW Remote Monitoring App allows real-time glucose data and alerts from Eversense users to be remotely shared with friends and family. The app allows up to five people to remotely receive updated readings approximately every five minutes, with the ability to easily view recent trends and alerts.“The value of remote monitoring in healthcare has never been clearer than in the last two years, with tools providing added peace of mind
for users and their support system,” said Elaine Anderson, Head of Senseonics CGM Business Unit at Ascensia Diabetes Care. “Managing diabetes requires continuous monitoring and decision making, and this app makes it easier for friends and family to be part of that process. Having a well-informed support network can reduce the burden placed on people with diabetes and we are excited to bring this useful tool to all Eversense users in Europe.”The Eversense NOW Remote Monitoring App is now available for both Apple and Android devices across Europe and can be downloaded via the Apple® App Store and Google Play™ Store.
I heard that there was a commercial on the Fox News Channel on the SENS CGM device. Anyone able to verify that?
what is driving this share to stay green while rest of the market is red
Your color blindness.😬
if you believe in the technology of SENS and you can wait for the 360 days approval and if no one comes with better technology then it is matter of marketing the product.
The downward trend is an issue
Speculative stock
Maybe the device disapproval ?
market cap is 1.2 B, this will be $10 in 12 months
not really
what is this man down 30% all 2 months gains wiped out in 1 day. What is this mess?
Agree.
could not understand, nobody do this. Someone should investigate
-33% in hours... pffff
A lot of panicking, inexperienced investors were looking to cash in short term. I am long term with this stock.
Remember that the fiscal year financial earnings is in March. Between now and then, the sales are going to be low. Anticipate growth in the coming months. This will help with the stock price. Just need some patience.
yes i agree and investors are panic to sell it and big sell off volume. It hasn't hit my cost price so i'll keep it and see.
Why is going down that badly after FDA aproval?
Don't panic but you better set a loss ratio for yourself
it depends how much risk you can take
didnt risk much. Got 500 shares in april-may 2021. Mid price 2.05, after first strong movement up.
This is bad guys see the reality
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.